David Tuong and Arthur Wong break down Johnson & Johnson's (JNJ) earnings beat, highlighting strong growth from key oncology and immunology drugs, including Darzalex and Tremfya. They discuss how the company's pipeline could help offset the upcoming Stelara patent cliff, while also examining medical technology trends and ongoing talc litigation risks.